Evidence map›Paper›PMID 37837527›Full record

ArticleAdvances in therapy2023

Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease.

Anders Løkke, Luca Castello, Pedro Pinheiro Martins, Stéphane Soulard, Ole Hilberg

Abstract read
In one paragraph

Article in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. BMJ open · 2026
    Article
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Article
  8. Article
  9. Sarcopenia in interstitial lung disease.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anders LøkkeDepartment of Medicine, Lillebaelt Hospital, Vejle, Denmark.ORCID http://orcid.org/0000-0002-6905-4141
Luca CastelloAdRes HE&OR, Turin, Italy.ORCID http://orcid.org/0009-0008-6014-0132
Pedro Pinheiro MartinsBoehringer Ingelheim bv, Amsterdam, The Netherlands.
Stéphane SoulardBoehringer Ingelheim bv, Amsterdam, The Netherlands. stephane.soulard@boehringer-ingelheim.com.ORCID http://orcid.org/0000-0003-1970-6823
Ole HilbergDepartment of Medicine, Lillebaelt Hospital, Vejle, Denmark.ORCID http://orcid.org/0000-0002-3075-3463

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionProgression of fibrosis in interstitial lung diseases (ILD) has been associated with poor prognosis, lower quality of life for patients and caregivers, and higher healthcare costs. This study estimated the burden of disease and productivity loss of progressively fibrosing ILD, focusing on progressive pulmonary fibrosis other than idiopathic pulmonary fibrosis (non-IPF PPF) and systemic sclerosis-associated ILD (SSc-ILD) in the European Economic Area (EEA).

methodsAn economic model was built to estimate the clinical burden of SSc-ILD and non-IPF PPF. The model was based on published data on disease prevalence and disease burden (in terms of comorbidities, exacerbations, and deaths) as well as on productivity loss (in terms of sick days, early retirement, permanent disability, and job loss). Aggregate income loss was obtained by multiplying productivity loss by the median daily income in each country/area of investigation. A sensitivity analysis was performed to test the impact of the variability of the model assumptions.

resultsIn the whole EEA, a total of 86,794 and 13,221 individuals were estimated to be affected by non-IPF PPF and SSc-ILD, respectively. Estimated annual sick days associated with the diseases were 3,952,604 and 672,172, early retirements were 23,174 and 5341, permanently disabled patients were 41,748 and 4037, and job losses were 19,789 and 2617 for non-IPF PPF and SSc-ILD, respectively. Annual exacerbations were estimated to be 22,401-31,181 and 1259-1753, while deaths were 5791-6171 and 572-638 in non-IPF PPF and SSc-ILD, respectively. The estimated annual aggregate income loss in EEA, accounting for losses due to annual sick days, early retirements, and permanently disabled patients, was €1433 million and €220 million in non-IPF PPF and SSc-ILD, respectively. The productivity loss due to job losses was €194 million and €26 million in non-IPF PPF and SSc-ILD, respectively. The main driver of aggregate income loss variability was the prevalence.

conclusionThe impact of non-IPF PPF and SSc-ILD on society is definitely non-negligible. Actions to reduce the burden on our societies are highly needed.

Indexed as

Idiopathic Pulmonary FibrosisLung Diseases, InterstitialScleroderma, SystemicCost of IllnessFibrosisHumansQuality of LifeDisease burdenIncome lossIndirect costsProductivity lossProgressive fibrosing interstitial lung diseaseSystemic sclerosis

Identifiers

PMID37837527
PMCPMC10611590

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.